Navigation Links
Hepatitis C Virus RNA Quantitative bDNA with Reflex to Qualitative PCR

ProductsHepatitis C Virus RNA Quantitative bDNA with Reflex to Qualitative PCR
Company ARUP Laboratories
Item Hepatitis C Virus RNA Quantitative bDNA with Reflex to Qualitative PCR
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. NOW® Hepatitis B Test
2. Autoimmune Hepatitis Panel Pluswith Reflex to Titers
3. Autoimmune Hepatitis Panelwith Reflex to ANA IFA Titer
4. Hepatitis A Virus Antibodies (Total)
5. Hepatitis A Virus Antibody, IgM
6. Hepatitis A Virus Panel
7. Hepatitis B Virus DNA Ultrasensitive Quantitative Real-Time PCR
8. Hepatitis B Virus Surface Antibody
9. Hepatitis B Virus Core Antibodies (Total)
10. Hepatitis B Virus Surface Antigen, Confirmation
11. Hepatitis B Virus Surface Antigenwith Reflex to Confirmation
The lower body blanket is utilized during surgical procedures covering the head, neck, arms and upper torso of your patient.
Soft yet durable, these single-patient use pads are designed to have the quality look of reusable pads but provide the hygienic advantages of disposability.
The lower body blanket is designed to be used primarily during surgery on the upper half of the body.
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and
Medicine Products:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... England Journal of Medicine suggests that patient...eral arterial disease(PAD) may benefit from walkin...ts. Kerry J. Stewart, Johns Hopkins University, Di... said that patients with PAD often experience pain...
...king up for a long time, like painting, plumbing, ...er, a new product called Necprotech developed by a...educe neck strain by a third. The product was deve...ging to a rock wall look easy, but a slip five yea...
...search & Quality recently conducted an analysis of... the importance of autopsies in revealing discrepa...rmative. The study indicated that the correct caus...to 23 per cent of cases. Out of this, in about 4 t...
...Medical Association published a recent comparative...Cincinnati who analyzed results from a telephone s...ion. The survey involved 2170 respondents who were...ing signs and risk factors. This was compared with...
Other Medicine News:
(Date:10/8/2008)...ew Zanolimumab Program to be Discontinued and Head... Results of its Portfolio Review; Zanolimumab Pro...e the Number of Empl...l/ -- Genmab A/S (OMX: GEN),announced today that i...ax-CD4(R)). In addition, as a result of a portfoli...
(Date:10/8/2008)...US clinical program to evaluate TAXUS(R) Element(T... Stent, NATICK, Mass., Oct. 8 /PRNewswire-First... ) today announced that it has completed enrollmen...ompany,s third-generation,TAXUS(R) Element(TM) pac...al program has enrolled nearly 1,500 patients at 1...
(Date:10/8/2008)...YON, France, Oct. 8 /- Vical Incorpor... clinical data and new nonclinical data,demonstrat...e broadly,applicable in DNA- and protein-based inf...vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vical...ill present the data today,Wednesday, October 8, ...
(Date:10/7/2008)...AN DIEGO, Oct. 7 /- Prometheus Labora...oday announced findings from its,development of PR...od test,for irritable bowel syndrome (IBS). The fi...ssion of particular biomarkers in blood samples,be... of these biomarkers,combined with a proprietary ...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 1STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 2STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 3STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 4VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 1VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 2VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 3VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 4Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 1Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 2Isolagen Inc Completes Enrollment in Isolagen Therapy 28TM 29 Phase II III Acne Scar Study 1520 3Legal exposure to asbestos like material linked to lung damage 25 years later 14381 1Legal exposure to asbestos like material linked to lung damage 25 years later 14381 2Legal exposure to asbestos like material linked to lung damage 25 years later 14381 3
...BUSINESS WIRE)--Jun 5, 2007 - Gloucester,Pharmaceu...,development company, today announced that data fo...ymphoma (CTCL) and peripheral,T-cell lymphoma (PTC...cal Oncology (ASCO) Annual Meeting being held in C...rim analysis of a phase II,study of romidepsin spo...
...how Antibodies Against Cancer-Causing Virus,Types ...an Natural,Infection Levels, CHICAGO, June 05, 200...18 months after the first of a three-dose regimen,... the GlaxoSmithKline,(GSK) cervical cancer candida...most common cancer-causing human papillomavirus,ty...
Other Medicine Technology:Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 2Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5